Rationale and design of a prospective, multicentre, stop tyrosine kinase inhibitor trial of paediatric patients with chronic myeloid Leukaemia with sustained complete molecular response (STKI-14)

Akiko Kada, Haruko Shima, Chikako Tono, Yuki Yuza, Hidemitsu Kurosawa, Akihiro Watanabe, Masaki Ito, Hideko Uryu, Kiyoko Kamibeppu, Nobutaka Kiyokawa, Souichi Adachi, Akiko M. Saito, Akihiko Tanizawa, Hiroyuki Shimada

Research output: Contribution to journalArticle

Abstract

Chronic myeloid leukaemia (CML) is a relatively rare disease in children, accounting for 2-3% of all paediatric leukaemia cases. Generally, children with CML can avoid hematopoietic stem cell transplantation and achieve molecular responses with tyrosine kinase inhibitors (TKI). However, CML stem cells are thought to survive in many patients, even after TKI treatment. Many aspects of the toxic effects of prolonged exposure to TKIs during childhood remain unclear, particularly those regarding growth impairment. This lack of clarity underscores the importance of the present clinical trial, which aims to clarify the feasibility of treatment-free remission (TFR) in children following TKI treatment. We aim to examine the long-term outcomes and complications of TKIs before and after cessation to better understand the unknown complications that could arise in adulthood. This trial targets patients who were diagnosed with CML at an age younger than 20 years, were in the chronic or accelerated phase at initial diagnosis and remained in complete molecular remission for at least 2 years after TKI administration. We will examine the utility of TKI cessation and assess the treatment results of patients who resumed TKI therapy after losing a major molecular response. We will also investigate factors related to the feasibility of a TFR after TKI cessation.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalHiroshima Journal of Medical Sciences
Volume67
Issue number1
Publication statusPublished - 2018 Mar 1

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Pediatrics
Myeloid Progenitor Cells
Therapeutics
Withholding Treatment
Poisons
Hematopoietic Stem Cell Transplantation
Rare Diseases
Leukemia
Clinical Trials
Growth

Keywords

  • Children
  • Chronic myeloid leukaemia
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rationale and design of a prospective, multicentre, stop tyrosine kinase inhibitor trial of paediatric patients with chronic myeloid Leukaemia with sustained complete molecular response (STKI-14). / Kada, Akiko; Shima, Haruko; Tono, Chikako; Yuza, Yuki; Kurosawa, Hidemitsu; Watanabe, Akihiro; Ito, Masaki; Uryu, Hideko; Kamibeppu, Kiyoko; Kiyokawa, Nobutaka; Adachi, Souichi; Saito, Akiko M.; Tanizawa, Akihiko; Shimada, Hiroyuki.

In: Hiroshima Journal of Medical Sciences, Vol. 67, No. 1, 01.03.2018, p. 7-13.

Research output: Contribution to journalArticle

Kada, Akiko ; Shima, Haruko ; Tono, Chikako ; Yuza, Yuki ; Kurosawa, Hidemitsu ; Watanabe, Akihiro ; Ito, Masaki ; Uryu, Hideko ; Kamibeppu, Kiyoko ; Kiyokawa, Nobutaka ; Adachi, Souichi ; Saito, Akiko M. ; Tanizawa, Akihiko ; Shimada, Hiroyuki. / Rationale and design of a prospective, multicentre, stop tyrosine kinase inhibitor trial of paediatric patients with chronic myeloid Leukaemia with sustained complete molecular response (STKI-14). In: Hiroshima Journal of Medical Sciences. 2018 ; Vol. 67, No. 1. pp. 7-13.
@article{9fcc81572d0540fbb6248ae3b39acad9,
title = "Rationale and design of a prospective, multicentre, stop tyrosine kinase inhibitor trial of paediatric patients with chronic myeloid Leukaemia with sustained complete molecular response (STKI-14)",
abstract = "Chronic myeloid leukaemia (CML) is a relatively rare disease in children, accounting for 2-3{\%} of all paediatric leukaemia cases. Generally, children with CML can avoid hematopoietic stem cell transplantation and achieve molecular responses with tyrosine kinase inhibitors (TKI). However, CML stem cells are thought to survive in many patients, even after TKI treatment. Many aspects of the toxic effects of prolonged exposure to TKIs during childhood remain unclear, particularly those regarding growth impairment. This lack of clarity underscores the importance of the present clinical trial, which aims to clarify the feasibility of treatment-free remission (TFR) in children following TKI treatment. We aim to examine the long-term outcomes and complications of TKIs before and after cessation to better understand the unknown complications that could arise in adulthood. This trial targets patients who were diagnosed with CML at an age younger than 20 years, were in the chronic or accelerated phase at initial diagnosis and remained in complete molecular remission for at least 2 years after TKI administration. We will examine the utility of TKI cessation and assess the treatment results of patients who resumed TKI therapy after losing a major molecular response. We will also investigate factors related to the feasibility of a TFR after TKI cessation.",
keywords = "Children, Chronic myeloid leukaemia, Tyrosine kinase inhibitors",
author = "Akiko Kada and Haruko Shima and Chikako Tono and Yuki Yuza and Hidemitsu Kurosawa and Akihiro Watanabe and Masaki Ito and Hideko Uryu and Kiyoko Kamibeppu and Nobutaka Kiyokawa and Souichi Adachi and Saito, {Akiko M.} and Akihiko Tanizawa and Hiroyuki Shimada",
year = "2018",
month = "3",
day = "1",
language = "English",
volume = "67",
pages = "7--13",
journal = "Hiroshima Journal of Medical Sciences",
issn = "0018-2052",
publisher = "Hiroshima University School of Medicine",
number = "1",

}

TY - JOUR

T1 - Rationale and design of a prospective, multicentre, stop tyrosine kinase inhibitor trial of paediatric patients with chronic myeloid Leukaemia with sustained complete molecular response (STKI-14)

AU - Kada, Akiko

AU - Shima, Haruko

AU - Tono, Chikako

AU - Yuza, Yuki

AU - Kurosawa, Hidemitsu

AU - Watanabe, Akihiro

AU - Ito, Masaki

AU - Uryu, Hideko

AU - Kamibeppu, Kiyoko

AU - Kiyokawa, Nobutaka

AU - Adachi, Souichi

AU - Saito, Akiko M.

AU - Tanizawa, Akihiko

AU - Shimada, Hiroyuki

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Chronic myeloid leukaemia (CML) is a relatively rare disease in children, accounting for 2-3% of all paediatric leukaemia cases. Generally, children with CML can avoid hematopoietic stem cell transplantation and achieve molecular responses with tyrosine kinase inhibitors (TKI). However, CML stem cells are thought to survive in many patients, even after TKI treatment. Many aspects of the toxic effects of prolonged exposure to TKIs during childhood remain unclear, particularly those regarding growth impairment. This lack of clarity underscores the importance of the present clinical trial, which aims to clarify the feasibility of treatment-free remission (TFR) in children following TKI treatment. We aim to examine the long-term outcomes and complications of TKIs before and after cessation to better understand the unknown complications that could arise in adulthood. This trial targets patients who were diagnosed with CML at an age younger than 20 years, were in the chronic or accelerated phase at initial diagnosis and remained in complete molecular remission for at least 2 years after TKI administration. We will examine the utility of TKI cessation and assess the treatment results of patients who resumed TKI therapy after losing a major molecular response. We will also investigate factors related to the feasibility of a TFR after TKI cessation.

AB - Chronic myeloid leukaemia (CML) is a relatively rare disease in children, accounting for 2-3% of all paediatric leukaemia cases. Generally, children with CML can avoid hematopoietic stem cell transplantation and achieve molecular responses with tyrosine kinase inhibitors (TKI). However, CML stem cells are thought to survive in many patients, even after TKI treatment. Many aspects of the toxic effects of prolonged exposure to TKIs during childhood remain unclear, particularly those regarding growth impairment. This lack of clarity underscores the importance of the present clinical trial, which aims to clarify the feasibility of treatment-free remission (TFR) in children following TKI treatment. We aim to examine the long-term outcomes and complications of TKIs before and after cessation to better understand the unknown complications that could arise in adulthood. This trial targets patients who were diagnosed with CML at an age younger than 20 years, were in the chronic or accelerated phase at initial diagnosis and remained in complete molecular remission for at least 2 years after TKI administration. We will examine the utility of TKI cessation and assess the treatment results of patients who resumed TKI therapy after losing a major molecular response. We will also investigate factors related to the feasibility of a TFR after TKI cessation.

KW - Children

KW - Chronic myeloid leukaemia

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85053674058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053674058&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 7

EP - 13

JO - Hiroshima Journal of Medical Sciences

JF - Hiroshima Journal of Medical Sciences

SN - 0018-2052

IS - 1

ER -